Finacea Foam Approved for Mild to Moderate Rosacea

The U.S. Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam, 15% (Bayer HealthCare) for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea Foam compared to foam vehicle (without azelaic acid) in the topical treatment of...

Articles

Finacea Foam Approved for Mild to Moderate Rosacea

The U.S. Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam,...

Web Marketing Overlooks Men Seeking Cosmetic Procedures

A recent study published online in the Aesthetic Surgery Journal (June 16,...

Choose Skin Health, a skin cancer screening program offered by the American Society...

Suneva Medical announced the closing of a $15 million equity investment by...

Products

Instant Facelift

The 60 Second Face Lift from Donna Bella Luxury Skin Care features DMAE,...

Mattifying Sunblock

SkinCeuticals Physical Matte UV Defense SPF 50 is a 100% physical sunscreen...

Probiotic Exfoliation

Mybody GLOWBIOTICS Probiotic Instant Resurfacing Pads are formulated with...

Periorbital Repair

The NIA24 Intensive Eye Treatment minimizes the appearance of fine lines,...

Finacea Foam Approved for Mild to Moderate Rosacea

The U.S. Food and Drug Administration (FDA) has approved Finacea (azelaic acid) Foam, 15% (Bayer HealthCare) for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea Foam compared to foam vehicle (without azelaic acid) in the topical treatment of papulopustular rosacea. In the two multicenter, randomized, double-blind, vehicle-controlled, 12-week clinical trials, Finacea Foam was evaluated in 1,362 subjects with papulopustular rosacea, with a mean lesion count of 21.3 (range 12 to 50) inflammatory papules and pustules. Subjects were randomized in a 1:1 ratio to receive either azelaic acid foam, 15% or the foam vehicle twice daily for 12 weeks. Treatment with Finacea Foam resulted in a higher Investigator’s Global Assessment (IGA) success rate compared to vehicle control (32.1% vs. 23.4% in Trial 1 and 43.4% vs. 32.5% in Trial 2), as well as a greater reduction in the mean nominal change of inflammatory lesion count from baseline to the end of the 12-week treatment period. The most frequently observed adverse reactions in ≥ 0.5% of subjects included local application site...

Web Marketing Overlooks Men Seeking Cosmetic Procedures

A recent study published online in the Aesthetic Surgery Journal (June 16, 2015) suggests that plastic surgeons could be doing more to attract the growing number of male patients seeking aesthetic treatments and that providers could benefit from incorporating male patients into their practice models.

Researchers from the New York University Department of Plastic Surgery reviewed the first 10 Google listings for plastic surgeons in each of the 48 contiguous states based on the gender of the first 10 images featured, presence of a male services section and which procedures were offered to men. They found that only 22% of the 453 websites featured a male services page and only 5% of 4,239 images reviewed across the sites featured men. The most common procedures marketed to men on the sites with dedicated pages include: gynecomastia (90%), liposuction (78%), blepharoplasty (60%), facelift (45%), abdominoplasty (40%), rhinoplasty (38%), Botox (38%) and fillers (25%).

Photo copyright Getty Images.

ASAE Honors ASDS Skin Cancer Program

Choose Skin Health, a skin cancer screening program offered by the American Society for Dermatologic Surgery (ASDS), has received the national 2015 Power of A award from the American Society of Association Executives (ASAE). The Power of A award annually recognizes organizations with programs that have a positive impact both nationally and internationally.

Choose Skin Health, now in its sixth year, is a joint effort between ASDS and Neutrogena in which ASDS members provide free skin cancer screenings and work to educate people about the importance of early detection. Neutrogena offers members a variety of free supplies for the screenings, including forms, brochures, sunscreen samples and marketing materials. The ASDS reported that one in ten people attending the free screenings is diagnosed with skin cancer and that by the end of 2014, the program had provided 14,854 free screenings.

“Our goals are to increase the number of community screenings and highlight the importance of sun protection and regular skin examinations,” said George J. Hruza, MD, president of the ASDS. “This program has the power to save lives and promote lifelong habits that lead to healthy skin.”

“Congratulations to ASDS for helping to...